High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV – but HIV viremia matters?
Xinling Xu, Jan Vesterbacka, Soo Aleman, Piotr Nowak
Abstract
Our clinical trial of SARS-COV-2 mRNA vaccine in 90 HIV-infected persons on antiviral treatment demonstrated high seroconversion rate and high levels of spike IgG antibodies after two doses of vaccine. The vaccine was well tolerated and not associated with HIV RNA blips. However, the levels of spike IgG antibodies were lower in HIV patients than in healthy controls, especially among those with HIV RNA more than 50 copies/ml at baseline.
Topics & Concepts
SeroconversionMedicineViremiaVirologyVaccinationAntibodyHuman immunodeficiency virus (HIV)ImmunologyLentivirusAIDS VaccinesHIV vaccineClinical trialMessenger RNAVaccine trialViral diseaseImmunogenicityVirusAntibody responseImmunopathologyCohortVaccine efficacySARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testingAnimal Virus Infections Studies